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In Brief
Through whole-exome sequencing of
annotated colorectal tumors, Giannakis
et al. identify additional colorectal cancer
driver genes and correlate high
neoantigen load with increased
lymphocytic infiltration and improved
survival. They also find positive selection
for HLA mutations in immune-cell-
infiltrated tumors. These results may
inform immunotherapeutic approaches in
colorectal cancer.
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http://dx.doi.org/10.1016/j.celrep.2016.03.075SUMMARY
Large-scale genomic characterization of tumors
from prospective cohort studies may yield new
insights into cancer pathogenesis. We performed
whole-exome sequencing of 619 incident colorectal
cancers (CRCs) and integrated the results with tu-
mor immunity, pathology, and survival data. We
identified recurrently mutated genes in CRC, such
as BCL9L, RBM10, CTCF, and KLF5, that were not
previously appreciated in this disease. Furthermore,
we investigated the genomic correlates of immune-
cell infiltration and found that higher neoantigen
load was positively associated with overall lym-
phocytic infiltration, tumor-infiltrating lymphocytes
(TILs), memory T cells, and CRC-specific survival.
The association with TILs was evident even within
microsatellite-stable tumors. We also found positive
selection of mutations in HLA genes and other com-
ponents of the antigen-processing machinery in
TIL-rich tumors. These results may inform immuno-
therapeutic approaches in CRC. More generally,
this study demonstrates a framework for futureThis is an open access article undintegrative molecular epidemiology research in colo-
rectal and other malignancies.INTRODUCTION
Large-scale cancer sequencing efforts have advanced our
understanding of the genomic landscape of many malignancies
(Garraway and Lander, 2013). However, a common drawback of
comprehensive genomic studies has been the lack of detailed
demographic, epidemiologic, and clinical annotations for cancer
cases (Cancer Genome Atlas Network, 2012). Together with
tumor molecular profiling, such annotations can be used to
discover potentially actionable tumor biomarkers, which may
change medical practice through lifestyle or pharmacologic
intervention (Liao et al., 2012). Another limitation of many tumor
sequencing studies has been their limited statistical power to
identify significantly mutated genes that have an intermediate
or lower frequency of mutation (e.g., <5% frequency). This
‘‘long tail’’ of cancer driver genes can be explored by increasing
the number of samples that are sequenced in each tumor type
(Lawrence et al., 2014).
Over the past several decades, cancer epidemiologists have
invested considerable effort in developing large and exquisitely
annotated cohort studies. Two prominent examples includeCell Reports 15, 857–865, April 26, 2016 ª 2016 The Authors 857
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Figure 1. Overview of the IntegrativeMolec-
ular Epidemiology Approach Employed in
the NHS and HPFS Cohorts
Participant follow-up used biennial question-
naires. Patients who developed CRC underwent
resection of tumor and adjacent normal tissue,
followed by formalin fixation, pathologic charac-
terization, and WES.the Nurses’ Health Study (NHS), involving 121,701 women
who were followed since 1976, and the Health Professionals
Follow-up Study (HPFS), involving 51,529 men followed since
1986. Both studies have accumulated diet, lifestyle, exposure,
and survival data on thousands of cancer patients, in conjunction
with archived tumor specimens from participants diagnosed
with the most common malignancies. These unique annotations
have offered insight into various aspects of cancer epidemiology
and tumor-environment interactions (Liao et al., 2012; Nishihara
et al., 2013).
The integration of genomic data with epidemiologic and
pathologic data offers appealing discovery opportunities in
colorectal cancer (CRC), a molecularly heterogeneous disease
(Cancer Genome Atlas Network, 2012) that arises and pro-
gresses in the context of many diverse environmental influences
and a complex tumor and immune-cell microenvironment (Ogino
et al., 2011). It has been demonstrated that microsatellite insta-
bility-high (MSI-high) colorectal carcinomas are associated
with high-level immune infiltrates (Jass et al., 1998), that the im-
mune contexture in colorectal carcinomas carries prognostic
significance (Galon et al., 2006; Ogino et al., 2009), and that
MSI-high tumors respond to immune checkpoint blockade (Le
et al., 2015). Across cancers, it has been increasingly recognized
that some somatically mutated genes can result in amino acid858 Cell Reports 15, 857–865, April 26, 2016changes that can generate immunogenic
peptides (called neoantigens) and can
participate in tumor-specific immune
responses (Saeterdal et al., 2001; Schwi-
talle et al., 2008; Schumacher and
Schreiber, 2015). Taken together, these
observations suggest a biologically and
therapeutically significant interplay be-
tween genomics and immune response
in CRC. However, few studies have
directly examined the totality of neoanti-
gens measured from tumor whole-exome
sequencing (WES) in relation to examina-
tion of in situ immune-cell infiltration in
matched patient samples, and such an
analysis has not been performed in mi-
crosatellite-stable (MSS) tumors.
To add comprehensive genomic char-
acterization to large-scale epidemio-
logic cohorts, we performed WES on
619 uniquely annotated archival tumor-
normal tissue pairs from the NHS and
the HPFS. We identified significantly
mutated genes that were previously un-appreciated in this disease and linked tumor neoantigen loads
and other immune-related genomic aberrations to immune-cell
infiltration and prognosis in CRC.
RESULTS
Overview of Approach and WES
Our approach for integrating CRC genomic data with patho-
logic characterization of immune infiltration and clinical out-
comes is shown in Figure 1. The NHS and the HPFS represent
two U.S.-wide prospective cohorts that have been followed for
40 and 30 years, respectively, by biennial questionnaires (Liao
et al., 2012). Throughout the course of follow-up, participants
diagnosed with colorectal carcinoma underwent resection of
tumor and adjacent normal tissue, which were subsequently
fixed in formalin and embedded in paraffin. We constructed tis-
sue microarrays (TMAs) when tissue was sufficient (Chan et al.,
2007). These tumor tissues were extensively characterized with
pathologic examinations of H&E-stained sections and immuno-
histochemistry analyses to assess their tumor grade, stage,
neoplastic cellularity, percentage of necrosis, and immune infil-
trates (Ogino et al., 2009; Nosho et al., 2010).
We performed WES on 619 cases with formalin-fixed paraffin-
embedded (FFPE) tumor and matched normal tissue pairs from
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Figure 2. Long Tail of Significantly Mutated Genes in Non-hypermutated CRC
Dark blue: genes identified in the NHS and HPFS but also previously reported in other large-scale sequencing studies of CRC (Cancer Genome Atlas Network,
2012; Seshagiri et al., 2012; Lawrence et al., 2014). Red: genes identified in the NHS and HPFS only. Common protein function categories and major CRC
signaling pathways are color coded next to significantly mutated genes. Gray bars, lower panel: log10 q value. Dashed line indicates q = 0.1.the NHS and the HPFS (Table S1). The average sequencing
coverage across all samples was 903, with an average of 87%
of bases covered at 203 (Figure S1; Table S2). Thus, these re-
sults affirm the feasibility of massively parallel sequencing in
FFPE tumor samples (Van Allen et al., 2014) and further extend
it to decades-old archival specimens. The WES mean target
coverage per sample and the library complexity obtained from
these archived FFPE tissue blocks inversely correlated with
the years since formalin fixation (Spearman’s rank correlation
coefficient = 0.33, p value = 5.8 3 1030 for coverage; Spear-
man’s rank correlation coefficient = 0.48, p value = 6.2 3 1069
for complexity)—but not with the percentage of necrotic tis-
sue within a block, as determined by pathologic examination
(Figure S2).
Significantly Mutated CRC Genes
Using the somatic mutations, including single-nucleotide vari-
ants (SNVs) and small insertions or deletions (indels) detected
in the WES data (Table S3), we next identified the recurrently
mutatedgenes that reached statistical significance in this dataset
(Figure 2; Tables S4 and S5 for non-hypermutated and hypermu-
tated tumors, respectively). Here, we employed the MutSigCV
suite of computational tools (Lawrence et al., 2014), which take
into account regional heterogeneity in mutation rates across the
genome. In 488 non-hypermutated tumors, we found 90 signifi-
cantly mutated genes that include most genes observed in the
Cancer Genome Atlas Network (2012) analysis of CRC, as well
as RNF43, which we described to be frequently mutated in this
disease (Giannakis et al., 2014). Among these 90 genes, 73 genes
were new to CRC in terms of statistical designation as driver
genes (Figure 2). This is largely because previous large-scale
sequencing studies of CRC either were not powered to detect
statistical significance at the requisite mutational frequencies
or did not identify the genes (Cancer Genome Atlas Network,2012; Seshagiri et al., 2012; Lawrence et al., 2014). Putative func-
tions for these genes range from kinase activity to DNA and RNA
binding (Figure 2). Pathways critical in CRC pathogenesis (Can-
cerGenomeAtlasNetwork, 2012), such asWNT, RAS, and trans-
forming growth factor b (TGF-b) signaling, were well represented
in the long tail of significantly mutated genes.
The list of cancer genes from this CRC cohort includes known
driver genes in other malignancies, such asPTEN andRB1; WNT
signaling genes, such as B cell CLL/lymphoma 9-like (BCL9L)
and transcription factor 7 (TCF7) genes; and RNA processing
genes, including RBM10 and RBM12. In addition, we identified
recurrent mutations in CCCTC-binding factor (CTCF), which
co-localizes with cohesins to affect transcription (Katainen
et al., 2015); Krueppel-like factor 5 (KLF5), a Zn-finger transcrip-
tion factor that has been implicated in cancer-stem cell regula-
tion (Nakaya et al., 2014); and TGIF1, which is a co-repressor
of TGF-b signaling. These results demonstrate the potential for
gaining insights into CRC pathogenesis by exploring the long
tail of significantly mutated genes in CRC.
Neoantigen Load and Immune-Cell Infiltration
Apart from altering gene function in a way that contributes to
carcinogenesis, tumor somatic mutations may affect tumor
progression by generating novel peptides that in turn may be
recognized by the host immune system as foreign, i.e., neoanti-
gens (Schumacher and Schreiber, 2015), and hence elicit strong
anti-tumor immunity. In CRC particularly, immune infiltration has
been demonstrated to have prognostic relevance (Galon et al.,
2006; Ogino et al., 2009), but the antigenic determinants of this
response have not been elucidated. To comprehensively char-
acterize the immunogenic potential of mutations in CRC, we pro-
ceeded to predict the number of immunogenic peptides in each
tumor sample based on its somatic mutation profiling. We first
determined the human leukocyte antigen (HLA) class I type ofCell Reports 15, 857–865, April 26, 2016 859
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Figure 3. Breakdown of the Total Number of Somatic Mutations and
Predicted Neoantigens by Mutation Typeeach sample (Shukla et al., 2015) and then used mutations
to predict neopeptides that bind with high affinity (<500 nM) to
personal HLA molecules (Rajasagi et al., 2014). Frameshift
indels generated a proportionally higher number of neoantigens
than did SNVs (Figure 3). We ranked the neopeptides by fre-
quency and found that significantly mutated CRC genes such
as RNF43, KRAS, and NRAS contain recurrent neopeptides
(Table S6).
We hypothesized that neoantigen load might be associated
with the density of immune infiltration in CRC. In 525 tumor-
normal pairs that underwent WES, we performed pathologic
examination on whole tumor tissue sections and graded each
of four components of lymphocytic reactions (on a 0–3 scale)
as previously described (Ogino et al., 2009). These include the
Crohn’s-like lymphocytic reaction, the peritumoral reaction
(discrete lymphoid nodules surrounding the tumor), the intratu-
moral periglandular reaction (lymphocytes within tumor stroma),
and tumor-infiltrating lymphocytes (TILs, defined as lympho-
cytes on top of cancer cells). The overall lymphocytic score
(ranging from 0–12) was composed of the sum of scores for
these four components. Overall lymphocytic score, as well as
each of the four components, has previously been associated
with longer survival of CRC patients in the NHS and HPFS
cohorts (Ogino et al., 2009).
Integrating these pathologic and neoantigen data revealed
that higher neoantigen load was associated with increased over-
all lymphocytic score in CRC (Spearman’s rank correlation coef-
ficient = 0.29, p value = 2.6 3 1011; Figure 4A). The correlation
was also significant at two additional neopeptide affinity cutoffs
of 150 and 50 nM (Spearman’s rank correlation coefficient =
0.30, p value = 1.53 1012, and Spearman’s rank correlation co-
efficient = 0.32, p value = 9.3 3 1014, respectively). When we
examined the individual lymphocytic reaction components, neo-
antigen load was most significantly associated with TILs and the
Crohn’s-like reaction (Spearman’s rank correlation coefficient =
0.36, p value = 2.03 1019, and Spearman’s rank correlation co-
efficient = 0.27, p value = 6.1 3 1010, respectively; Figure 4B;
Table S7). These findings raised the possibility that neopeptides
might be recognized by lymphocytes (TILs) that are in immediate
contact with tumor cells. Our results may also posit an important
role for tertiary lymphoid structures such as the Crohn’s-like
reaction in colorectal tumor-directed immune responses.
To identify specific T cell subsets that might correlate with
neoantigen load, for 299 samples, we quantified the densities860 Cell Reports 15, 857–865, April 26, 2016of CD3+ (total), CD8+ (cytotoxic), CD45RO+ (memory), and
FOXP3+ (regulatory) T cells by leveraging the TMA, immunohis-
tochemistry, and computer-assisted image analysis performed
previously on these cohorts (Nosho et al., 2010). We found that
the neoantigen load correlated significantly with CD45RO+
T cell density but not significantly with CD8+, CD3+, or FOXP3+
T cell density (Figure 4C; Table S7). These results support the
idea that prior neoantigen-directed tumor recognition drives
the generation of these T cell infiltrates in CRC.
It has been previously shown that MSI-high cancers have
increased immune infiltrates, and it has been proposed that
MSI-high tumors harbor more neoantigens (Galon et al., 2006;
Ogino et al., 2009). We found that MSI-high CRCs and tumors
harboring POLE exonuclease domain mutations were associ-
ated with a significantly higher neoantigen load when compared
to MSS cancers (Figure S3). When we restricted our analysis to
MSS POLE-wild-type cases, we found a significant association
between high neoantigen load and high degree of TILs (p value =
0.035 and p value = 0.015 for the comparison of TIL 2+ to TIL 1
and TIL 0 samples, respectively; Wilcoxon rank-sum test; Fig-
ure 4D). These findings suggest that even within MSS tumors,
neoantigen load is a genomic determinant for immune-cell infil-
tration in CRC.
Neoantigen Load and Survival
Previous studies have shown an improved prognosis in CRCs
with a high density of memory T cell or cytotoxic T cell infiltrates
(Galon et al., 2006; Ogino et al., 2009). Leveraging the extensive
clinical data collected on the NHS and HPFS participants, we
investigated the relationship between neoantigen load and pa-
tient survival. We found that an elevated neoantigen load was
associated with improved CRC-specific survival (log rank test,
p value = 0.004;multivariate hazard ratio = 0.57 [95%confidence
interval, 0.35–0.93], p value = 0.03; Figure 5A; Tables S8 and S9).
No significant difference in overall survival was observed (Fig-
ure 5B; Tables S8 and S9); this may reflect the large number of
non-cancer-related deaths in this population with a median
follow-up of 9.4 years (interquartile range, 5.8–13.1 years).
Positive Selection for HLA and Antigen-Processing
Machinery Mutations in Tumors with TILs
Given the relevance of neoantigens in determining immune infil-
trates in CRC, we hypothesized that alterations of HLA loci and
other antigen-processing machinery (APM) components might
undergo positive selection during tumor evolution in the setting
of an active antitumor immune response. We identified HLA
class I mutations using a computational algorithm that we
recently developed (Shukla et al., 2015) and found a total of 96
HLA mutations in 66 of 619 samples (11%). Of these, 27% (18
of 66 samples) had mutations in more than one HLA allele (Fig-
ure S4A). All 18 samples with multiple mutations in HLA alleles
had the hypermutated phenotype, while 71% (34 of 48 samples)
with only a single HLAmutation were hypermutated. The fraction
of putative loss-of-function events (nonsense, splice site, and
frameshift indels) was comparable between the hypermutated
(56%) and the non-hypermutated (57%) groups. The greatest
number of mutations was in exon 4, which codes for the T cell re-
ceptor (TCR) binding domain (Figure S4B). After normalizing for
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Figure 4. Correlation of Neoantigen Load with Immune-Cell Infiltration in CRC
(A) Correlation of neoantigen load with overall lymphocytic reaction score. The dotted line denotes a smoothing curve for all data points. The p value is calculated
by Spearman’s rank correlation test.
(B) Correlation of neoantigen load with individual components of lymphocytic reaction. The median number of neoantigens for each component score is plotted.
The p value is calculated by Spearman’s rank correlation test.
(C) Correlation between neoantigen load and density of immunohistochemically defined tumor-infiltrating T cell subsets. Numbers inside bars correspond to the
Spearman’s rank correlation coefficient. The p value is calculated by Spearman’s rank correlation test.
(D) Comparison of number of neoantigens among tumors with different TIL grades, with analysis restricted to the MSS POLE-wild-type subset. The p value is
calculated by Wilcoxon rank-sum test.exon length, exon 4 was still found to be most enriched for mu-
tations, indicating that abrogation of effective T cell interaction is
an important mechanism of immune escape in CRC. The selec-
tive pressure on the leader peptide domain (encoded by exon 1),
peptide binding domains (encoded by exons 2 and 3), and trans-
membrane domain (encoded by exon 5) was comparable (Fig-
ure S4C). No mutations were found in the cytoplasmic tail
domain, which is encoded by exons 6, 7, and 8. Of the 39%
(37 of 96) mutations in the peptide binding domains, 46% (17
of 37) mutations occurred in positions that come in direct contact
with the peptide and would be expected to profoundly affect
peptide binding, likely resulting in ineffective presentation of
the HLA:peptide complex to the immune system.
We subsequently correlated HLA mutations with pathologic
data of immune infiltration. We observed a significantly higher
frequency of HLA mutations in samples with higher TIL grading
(Figure 6A; Table S10). This correlation also held when taking
into account variations of overall mutation rates among samplesand when the analysis was restricted to MSS POLE-wild-type
tumors (Figure 6B; Table S10). These results suggest that HLA
gene mutations may undergo positive selection in tumors with
high immune infiltrates. In addition, mutated HLA alleles across
all samples were found to have more neoantigens than non-
mutated alleles after normalizing for number of coding mutations
in the patient (Wilcoxon rank-sum test, p value = 0.006), indica-
tive of a selection process by which the likelihood of an allele
being mutated is proportional to its contribution to the tumor’s
immunogenicity. This observation supports the hypothesis that
acquisition of HLA mutation is a plausible route for escaping im-
mune-based elimination in CRC. We also examined whether, in
aggregate, mutations in the APM pathway might be enriched in
tumors with high TILs. We found significant enrichment of these
mutations in TIL-rich tumors (Table S10). The APM pathway
includes proteins involved in major histocompatibility complex
class I (MHC class I) folding (CANX and HSPA5), the MHC
class I complex (HLA class I and B2M), and the endoplasmicCell Reports 15, 857–865, April 26, 2016 861
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A B Figure 5. Neoantigen Load and Survival in
CRC
(A and B) Kaplan-Meier curve for (A) CRC-specific
survival and (B) overall survival according to neo-
antigen load. High (n = 149) and medium-low
(n = 448) neoantigen groups were classified
as described in Experimental Procedures. The
p value is calculated by log rank test.reticulum (ER) peptide-loading complex (TAP, TAPBP, CALR,
and PDIA3; Figure 6C). Collectively, these results may indicate
positive selection for APM component mutations in tumors that
are under immune attack (Figure 7). This may have implications
for potential mechanisms of resistance when immunotherapy is
administered.
DISCUSSION
We performed WES on colorectal tumors from two widely stud-
ied epidemiologic cohorts and integrated the tumor genomic
data with detailed pathologic and clinical information in this
setting. Adding to the significant progress in characterizing the
molecular landscape of CRC (Cancer Genome Atlas Network,
2012; Seshagiri et al., 2012), new insights were gleaned by
exploring the long tail of significantly mutated genes that became
evident by sequencing larger numbers of tumors, as predicted
by earlier analyses (Lawrence et al., 2014). Newly recognized
candidate driver genes include kinases, transcription factors,
and RNA binding proteins (Figure 2). Featured in this list were
members of the WNT (BCL9L and TCF7), RAS (PRKCQ,
MAP2K1, andMAP2K7), and TGF-b (TGIF1) signaling pathways,
as well as the RNA processing machinery (RBM10 and RBM12),
which were not previously found to be significantly mutated in
CRC. BCL9L can act as a co-factor of WNT signaling in tumors
and has been shown, when overexpressed, to promote tumor
progression in mouse models of WNT-driven colon cancer
(Brembeck et al., 2011). The tumor suppressor PTEN has been
well described as significantly mutated in other malignancies
(Lawrence et al., 2014); the increased number of sequenced
samples in our study allowed PTEN to be identified as such in
CRC as well. RBM10 and RBM12 belong to the same family of
proteins involved in RNA splicing. Mutations in RBM10 were
described in lung and pancreatic adenocarcinomas and shown
to be associated with male sex and an improved prognosis,
respectively (Cancer Genome Atlas Research Network, 2014;
Witkiewicz et al., 2015). We also identified mutations in reprog-
ramming factor KLF5, which regulates the intestinal stem-cell
niche and, when deleted, can suppress colorectal oncogenesis
(Nakaya et al., 2014). Another transcriptional regulator that was
significantly mutated in our analysis wasCTCF. Our results com-
plement data showing that CTCF and cohesin-binding sites are862 Cell Reports 15, 857–865, April 26, 2016frequently mutated in CRC and positively
selected in MSS tumors (Katainen et al.,
2015). Our findings demonstrate the
potential to gain insight into CRC patho-
genesis by exploring the long tail of signif-
icantly mutated genes.In addition to their role in affecting normal cell function,
tumor somatic mutations can generate neoantigens, which can
be recognized by the host immune system (Schumacher and
Schreiber, 2015). A strength of large-scale sequencing analyses
is the comprehensive characterization of overall tumor immuno-
genicity.We identified knownCRCgenes such asRNF43,KRAS,
and NRAS to be the source of recurrent neopeptides, consistent
with a prior report (Angelova et al., 2015).
By incorporating the pathologic characterization of the
sequenced tumors, we found that neoantigen load was signifi-
cantly associated with immune-cell infiltrates—including overall
lymphocytic score and TILs. Moreover, the concomitant associ-
ation with CD45RO+ T cell subsets argues for the potential
importance of memory T cell responses in neoantigen-directed
tumor recognition. Supporting this premise, CD45RO+ cell den-
sity was previously identified as an independent favorable prog-
nostic factor in CRC (Nosho et al., 2010; Page`s et al., 2005).
Furthermore, neoantigen load was predictive of CRC-specific
survival in our analysis. This result is consistent with literature
demonstrating an improved survival in cancers that harbor
immunogenic mutations (Brown et al., 2014).
MSI-high CRCs have been shown to contain a higher degree
of immune infiltration (Jass et al., 1998); a likely explanation is
the presence of many more immunogenic mutations in these
tumors compared to their MSS counterparts. Here, analysis of
WES data revealed that MSI-high tumors harbored increased
numbers of neoantigens; in turn, these were correlated with
immune infiltrates. However, even in MSS tumors, neoantigen
load was a genomic determinant for immune-cell infiltration in
our analyses. In a phase II study, mismatch-repair-deficient tu-
mors were found to respond to checkpoint inhibition, whereas
no responses were seen in MSS CRC patients (Le et al., 2015).
Our findings suggest that a subset of MSS POLE-wild-type tu-
mors has a higher neoantigen load and harbors a higher number
of TILs. Such patients may represent an appealing molecular
context for future trials of immune checkpoint inhibitors. In addi-
tion, although we did not have the statistical power to demon-
strate an association with TILs in POLE-mutated colorectal
tumors, we speculate that they could be responsive to check-
point inhibition based on their increased neoantigen load.
We also identified and characterized HLA mutations in
CRC, demonstrating an enrichment of HLA mutations in the
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Figure 6. PositiveSelection forHLAandAPM
Mutations in Immune-Cell-Infiltrated Tumors
(A) Enrichment of HLA mutations in CRCs with
higher TIL scores. The p value is calculated by the
chi-square test.
(B) Enrichment of HLA mutations in MSS POLE-
wild-type CRCswith higher TIL scores. The p value
is calculated by the chi-square test.
(C) Enrichment of APM mutations in immune-cell-
infiltrated tumors. Highlighted genes are repre-
sentative components of the APM pathway, which
are mutated in NHS and HPFS tumors. Numbers
in parentheses indicate mutation frequencies
(percentage) in non-infiltrated versus infiltrated
tumors. Neopeptides are processed by the pro-
teasome, transported into the ER, and loaded onto
MHCs that, through vesicle transport, traffic to the
plasma membrane of tumor cells, where they can
be recognized by effector T cells.TCR binding domain of the protein. In addition, our results indi-
cate that HLA class I and other APM gene mutations may
undergo positive selection in CRCs that exhibit high TIL levels.
Thus, APM alterations may provide a mechanism of adaptive
resistance to the effects of immune infiltration. Tumor cells
that harbor such mutations may exhibit increased evolutionary
fitness in the face of immune infiltration, perhaps by impairing
their own neoantigen-presentation machinery and thereby
shielding themselves from T cells. Whether such tumors might
also prove more resistant to immune checkpoint inhibition
remains an open question.
In conclusion, we have integrated comprehensive genomic
data with clinical, epidemiologic, and pathologic annotations
linked to CRC in the NHS and HPFS cohort studies. We found
additional putative driver genes and identified neoantigen load
as a likely genomic determinant of immune infiltration in CRC.
Moreover, HLA and APM pathway mutations show evidence of
positive selection in tumors with infiltrating lymphocytes. These
results may inform patient selection for future CRC immuno-
therapy trials. More generally, large-scale genomic characteriza-
tion of expertly annotated prospective epidemiology cohorts
may offer new insights into pathophysiology and therapeutic
avenues relevant to multiple cancer types.
EXPERIMENTAL PROCEDURES
Specimens and Survival Data
All colorectal carcinoma and adjacent normal colorectal tissue samples were
collected according to Partners Human Research Committee institutional re-
view board-approved protocols, and informed consent was obtained from
all subjects. Patients were followed until death or January 2012, whichever
came first. The National Death Index was used to ascertain deaths of study
participants, and survival data were obtained on 597 individuals.
WES and Identification of Significantly Mutated Genes
Genomic DNA was extracted from tumor areas dissected from tissue sections
that were made from the FFPE blocks using the QIAGEN QIAamp DNA FFPE
Tissue Kit. We evaluated DNA quality using the Quant-iT Pico Green dsDNA-
assay Kit (Invitrogen). Sequencing data were generated as detailed previously
(Van Allen et al., 2014). In brief, whole-exome capture libraries were con-
structed from tumor and normal DNA after sample shearing, end repair,
phosphorylation, and ligation to barcoded sequencing adaptors. DNA then un-
derwent solution-phase hybrid capture with SureSelect v.2 Exome bait (AgilentTechnologies), followed by multiplexing of the samples and sequencing on Il-
lumina HiSeq 2000 instruments. The average coverage was 903 (Table S2).
We performed sequence analysis as previously described (Cibulskis et al.,
2013; Giannakis et al., 2014). We detected somatic mutations with the MuTect
algorithm (Cibulskis et al., 2013) and somatic indels by taking concordant
events identified by the Indelocator (http://www.broadinstitute.org/cancer/
cga/indelocator) and Strelka (Saunders et al., 2012) algorithms. To further filter
spurious SNV calls, we used Burrows-Wheeler Aligner BWA-MEM (http://bio-
bwa.sourceforge.net/) to realign sequenced reads associated with the muta-
tions to a set of sequences derived from the human reference assembly. To
remove artifacts that result from hydrolytic deamination of cytosine to form
uracil specifically in FFPE samples, we filtered out C > T mutations consistent
with a 20:1 single-strand bias based on read pair orientation. We used the
MutSigCV suite of tools (Lawrence et al., 2014) and manual curation to infer
significantly mutated genes. Hypermutated tumors are defined as those
with a mutation rate > 12/Mb. All analyses were carried out on human genome
build hg19.
HLA Typing, HLA Mutations, and Neoantigen Load Prediction
The HLA type for each sample was inferred using the POLYSOLVER
(POLYmorphic loci reSOLVER) algorithm (Shukla et al., 2015), which employs
a Bayesian classifier and selects and aligns putative HLA reads to an imputed
library of full-length genomic HLA allele sequences. These alignments are then
abasis for the inference step that incorporates the number andbasequalities of
aligned reads, the empirical library insert size distribution, and the population-
based allele frequencies. Mutations in HLA class I genes were detected using
thePOLYSOLVER-basedmutationdetection pipeline that takes a tumor-germ-
line exome pair as input and first characterizes the HLA alleles in the individual
by applying POLYSOLVER on the germline data. Putative HLA reads from both
the tumor and the germline exomes are then aligned to the inferred alleles sepa-
rately, and likely erroneous alignments are filtered out. Somatic changes are
subsequently identified by comparative evaluation of the aligned tumor and
germline files using the MuTect (Cibulskis et al., 2013) and Strelka (Saunders
et al., 2012) tools.
HLA-binding peptides per sample were identified by a neoantigen predic-
tion pipeline (Rajasagi et al., 2014) that used the somatic mutations
detected in an individual, as described earlier. We predicted the binding af-
finities of all possible 9- and 10-mer mutant peptides to the corresponding
POLYSOLVER-inferred HLA alleles using NetMHCpan (v.2.4; Nielsen et al.,
2007). To calculate the neoantigen load, we used all predicted binders with
affinity < 500 nM, unless otherwise noted.
Histopathologic Examination and Sample Characterization
H&E slides prepared from FFPE blocks were examined for tumor grade, necro-
sis, and other tumor characteristics through centralized pathology review
(by S.O.). For any given tumor, each of the four components of lymphocyticCell Reports 15, 857–865, April 26, 2016 863
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Figure 7. Model of Positive Selection for
HLA and APM Mutations in Tumors under
Immune Attackreaction (Crohn’s-like reaction, peritumoral reaction, intratumoral perigland-
ular reaction, and TILs) was scored as 0 (absent), 1 (mild), 2 (moderate), or 3
(marked), as previously described (Ogino et al., 2009). A subset of CRCs
was examined independently by another pathologist (K.I.), and Spearman’s
rank correlation coefficient was 0.59 for Crohn’s reaction, 0.67 for peritumoral
reaction, 0.56 for intratumoral periglandular reaction, 0.64 for TILs, and 0.68 for
the overall lymphocytic score. TMA construction and immunohistochemistry
for CD3, CD8, FOXP3, and CD45RO were performed as previously described
(Nosho et al., 2010). Immunohistochemically stained TMA slides were scanned
by an automated scanning microscope, and Ariol image analysis software
was used to quantify the positive nuclei (as the number per square millimeter)
in the neoplastic area of each sample. Using DNA from tumor tissue, MSI
status was analyzed with the use of 10 microsatellite markers (D2S123,
D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67, and
D18S487) as previously described (Liao et al., 2012). We used the term MSS
for non-MSI-high samples. We used the WES data to identify four MSS sam-
ples harboring mutations in the POLE exonuclease domain (p.Pro286Arg,
p.Val411Leu, and p.Ser459Phe).
Statistical Analysis
All p values are two sided. We used the Wilcoxon rank-sum test to compare
neoantigen load among POLE-mutated tumors, MSI-high tumors, and MSS
tumors and used Spearman’s rank correlation and Wilcoxon rank-sum tests
to compare neoantigen load and immune infiltrates. Locally weighted scatter-
plot smoothing was used to calculate the smoothing curve for neoantigen load
versus overall lymphocytic reaction score. In survival analyses, we used the
Kaplan-Meier method and log rank test, as well as Cox-proportional hazard
regression models to calculate the hazard ratio according to neoantigen
load, controlling for potential confounders. Specifically, we used a stage-strat-
ified model, adjusting for age, gender, tumor location, and tumor differentia-
tion. We verified that the proportionality assumptions for the Cox model
were met. In the analysis of CRC-specific survival, deaths as a result of other
causes were censored. Samples were classified as high for neoantigen load if
they had more than 450 calculated neoantigens, and remaining samples were
classified as medium-low for neoantigen load. This was the optimal cutoff
derived from a sensitivity analysis with the division between the high and the
medium-low neoantigen groups varying from 200 to 4,000 in neoantigen num-
ber with a step size of 50.We performed chi-square test and logistic regression
to assess enrichment of HLA and APM mutations in samples with higher TIL
scores. We adjusted for mutation rates in logistic regression models for HLA
and APM mutations. In addition to HLA, genes participating in the APM
pathway were annotated based on the Kyoto Encyclopedia of Genes and
Genomes’ (Kanehisa et al., 2014) ‘‘Antigen Processing and Presentation
Pathway.’’
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